ASP8273
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Jan 23, 2014 → Jun 14, 2017
NCT ID
NCT02192697About ASP8273
ASP8273 is a phase 1/2 stage product being developed by Astellas Pharma for Non-small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02192697. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03042013 | Phase 2 | Withdrawn |
| NCT02192697 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Non-small Cell Lung Cancer